Want to see FR:DBV full AI Analyst Report?
DBV Stock Chart & Stats
€2.37
€0.07(2.94%)
At close: 4:00 PM EDT
€2.37
€0.07(2.94%)
Day’s Range― - ―
52-Week Range€1.53 - €4.50
Previous CloseN/A
Volume603.12K
Average Volume (3M)1.17M
Market Cap
€537.82M
Enterprise Value€1.09B
Total Cash (Recent Filing)€174.90M
Total Debt (Recent Filing)€21.80M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Oct 28, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding314,388,800
10 Day Avg. Volume1,036,980
30 Day Avg. Volume1,167,850
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)3.28
Price to Sales (P/S)0.00
P/FCF Ratio-4.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)€3.13M
Bulls Say, Bears Say
Bulls Say
Low LeverageDebt of about €7.7M against €160.5M of equity indicates limited leverage, while assets of roughly €223.2M are primarily equity-funded. This provides greater solvency resilience and financial flexibility than a heavily indebted biotech as development spending continues.
Improving Free Cash Flow TrendAlthough free cash flow remains deeply negative, the reported improvement versus the prior period offers some evidence that cash deterioration has moderated. If sustained, better cash-flow performance could gradually reduce funding pressure and extend operational flexibility.
Focused EPIT PlatformA focused EPIT platform gives DBV a coherent development strategy centered on food allergies and immune-mediated conditions. Concentrating resources around Viaskin Peanut and related applications may support clearer clinical execution and future platform expansion.
Bears Say
Severe Operating LossesMinimal revenue combined with very large operating and net losses shows that DBV has not yet established economic scale. Persistently negative profitability limits internal funding capacity, increases reliance on capital raising, and raises the risk of continued shareholder capital erosion.
Heavy Cash BurnThe magnitude of operating and free-cash-flow deficits indicates substantial ongoing funding needs to sustain development. Continued cash consumption can constrain clinical investment, increase financing dependence, and leave the company more exposed if external funding becomes less available.
No Commercial Revenue BaseWithout recurring commercial product sales, DBV’s financial model depends on advancing candidates, securing approvals, and obtaining external financing or collaboration proceeds. This creates a structurally uncertain path to sustainable revenue and leaves funding needs elevated.
DBV Technologies News
DBV FAQ
What was DBV Technologies’s price range in the past 12 months?
DBV Technologies lowest stock price was €1.53 and its highest was €4.50 in the past 12 months.
What is DBV Technologies’s market cap?
DBV Technologies’s market cap is €537.82M.
When is DBV Technologies’s upcoming earnings report date?
DBV Technologies’s upcoming earnings report date is Oct 28, 2026 which is in 5 days.
How were DBV Technologies’s earnings last quarter?
DBV Technologies released its earnings results on Jul 16, 2026. The company reported -€0.021 earnings per share for the quarter, missing the consensus estimate of -€0.019 by -€0.002.
Is DBV Technologies overvalued?
According to Wall Street analysts DBV Technologies’s price is currently Overvalued.
Does DBV Technologies pay dividends?
DBV Technologies does not currently pay dividends.
What is DBV Technologies’s EPS estimate?
DBV Technologies’s EPS estimate is -0.03.
How many shares outstanding does DBV Technologies have?
DBV Technologies has 314,388,800 shares outstanding.
What happened to DBV Technologies’s price movement after its last earnings report?
DBV Technologies reported an EPS of -€0.021 in its last earnings report, missing expectations of -€0.019. Following the earnings report the stock price went down -7.275%.
Which hedge fund is a major shareholder of DBV Technologies?
Currently, no hedge funds are holding shares in FR:DBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DBV Technologies
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.